Nurix Therapeutics shares are trading higher after its deal with Seagen to develop a portfolio of degrader-antibody conjugates.
Portfolio Pulse from Benzinga Newsdesk
Nurix Therapeutics has entered into a deal with Seagen to develop a portfolio of degrader-antibody conjugates. This has led to an increase in Nurix's share prices.
September 07, 2023 | 1:49 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Seagen has entered into a partnership with Nurix Therapeutics to develop a portfolio of degrader-antibody conjugates.
While the partnership with Nurix Therapeutics is a positive development for Seagen, the news does not directly mention any impact on Seagen's share prices. Therefore, the short-term impact on Seagen's stock is neutral.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 80
POSITIVE IMPACT
Nurix Therapeutics' shares have increased following the announcement of a partnership with Seagen.
The partnership with Seagen to develop a portfolio of degrader-antibody conjugates is a positive development for Nurix Therapeutics. This has led to an increase in investor confidence, reflected in the rise in share prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100